Pulse Biosciences (PLSE) Cash & Equivalents (2015 - 2025)

Pulse Biosciences' Cash & Equivalents history runs 11 years deep, the most recent figure standing at $80.7 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 31.6% year-over-year to $80.7 million; the TTM figure through Dec 2025 stood at $80.7 million (down 31.6% YoY), while the FY2025 annual figure was $80.7 million, down 31.6% from the prior year.
• Cash & Equivalents was $80.7 million for Q4 2025 at Pulse Biosciences, down from $95.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $119.3 million in Q1 2025 to a low of $12.7 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $60.4 million across 5 years, with a median of $54.3 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents jumped 661.48% in 2021, then slumped 78.83% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $44.4 million in 2021, then soared by 30.67% to $58.0 million in 2022, then retreated by 23.47% to $44.4 million in 2023, then jumped by 166.06% to $118.0 million in 2024, then plunged by 31.6% to $80.7 million in 2025.
• The last three Cash & Equivalents figures came in at $80.7 million (Q4 2025), $95.2 million (Q3 2025), and $106.3 million (Q2 2025), per Business Quant data.